Skip to main content

Pharmaceutical Companies Explore New AI Applications

How can artificial intelligence (AI) technology improve traditional medicine? With 97 percent of all drug discovery programs reportedly failing, the development of a single new therapeutic involves an average cost of $2.6 billion. Helping to improve that process is a huge upside opportunity.

Today, the complex research framework that's involved in the discovery and development of new therapeutic products makes drug innovation an extremely laborious process, according to the latest worldwide market study by Frost & Sullivan.

Pharmaceutical AI Market Development

More than 60 percent of known diseases remain untreatable. Meanwhile, life sciences companies are making progress in the fields of gene and cell therapies, omics technologies, and smart molecules approaches, creating the need for advanced, cost-effective technologies that can parse large quantities of data.

"Pharmaceutical companies are increasingly recognizing the value of deploying AI-based platforms that can leverage data regarding gene mutations, protein targets, signaling pathways, disease events, and clinical trials to find hidden drug-disease correlations,” said Cecilia Van Cauwenberghe, senior analyst at Frost & Sullivan.

This technology will enable scientists to derive structured and unstructured data from multiple sources as never before. Moreover, strategic collaborations with IT vendors can help pharmaceutical companies establish a robust, AI-based pipeline as part of their portfolios and address new therapeutic areas.

AI-driven tools are encouraging companies to develop therapies for severely underserved areas and are also paving the way for precision medicine through a stratified therapeutics discovery and development approach.

Collaborations among database holders, AI developers, and drug manufacturers will facilitate the early development of multiple therapeutics, even those focused on treating rare and chronic diseases.

The leading companies are also empowered to make the most of scientific results and learning systems synergy to ensure a successful clinical translation of therapeutic, diagnostic, and theranostic developments. Some of the key applications of AI technologies in pharmaceuticals include:

  • Drug development: Aids in disease modeling, drug design and development, lead identification, and drug repurposing.
  • Candidates validation: Helps design and run pre-clinical trials, in silico/in vitro/in vivo studies, and investigational new drug (IND) process.
  • Clinical trials: Supports all processes, from designing the trial to patient identification through data collection, analysis, and report generation.
  • Regulatory approval: Facilitates the approval of application and process, labeling, and safety updates.
  • Precision medicine: Accelerates the development of preventive and personalized care, treatment surveillance, and omics adaptive models.

Outlook for Medical AI Application Growth

"Overall, there is a profound and growing scientific understanding of many metabolic and signaling pathways, especially at molecular and genomic levels, which encourages the use of sophisticated technologies to develop groundbreaking therapies," noted Van Cauwenberghe.

As the underlying causes of many diseases remain vague and imprecise, artificial intelligence-oriented approaches have emerged as the ideal mechanisms for finding novel treatments.

Popular posts from this blog

Digital Talent Demand Exceeds Supply in Asia-Pac

Even the savviest CEO's desire for a digital transformation advantage has to face the global market reality -- there simply isn't enough skilled and experienced talent available to meet demand. According to the latest market study by IDC, around 60-80 percent of Asia-Pacific (AP) organizations find it "difficult" or "extremely difficult" to fill many IT roles -- including cybersecurity, software development, and data insight professionals. Major consequences of the skills shortage are increased workload on remaining digital business and IT employees, increased security risks, and loss of "hard-to-replace" critical transformation knowledge. Digital Business Talent Market Development Although big tech companies' layoffs are making headlines, they are not representative of the overall global marketplace. Ongoing difficulty to fill key practitioner vacancies is still among the top issues faced by leaders across industries. "Skills are difficul

How Cloud Fuels Digital Business Transformation

Across the globe, many CEOs invested in initiatives to expand their digital offerings. User experience enhancements that are enabled by business technology were a priority in many industries. Worldwide end-user spending on public cloud services is forecast to grow 21.7 percent to a total of $597.3 billion in 2023 -- that's up from $491 billion in 2022, according to the latest market study by Gartner. Cloud computing is driving the next phase of digital transformation, as organizations pursue disruption through technologies like generative Artificial Intelligence (AI), Web3, and enterprise Metaverse. Public Cloud Computing Market Development "Hyperscale cloud providers are driving the cloud agenda," said Sid Nag, vice president at Gartner . Organizations view cloud computing as a highly strategic platform for digital transformation initiatives, which requires providers to offer new capabilities as the competition for digital business escalates. "For example, generativ

Mobile Device Market Still Awaiting Recovery

The mobile devices market has experienced three years of unpredictable demand. The global pandemic, geopolitical pressures, supply chain issues, and macroeconomic headwinds have hindered the sector's consistent growth potential. This extremely challenging environment has dramatically affected both demand and supply chains. It has led to subsequent inflationary pressures, leading to a worsening global cost of living crisis suppressing growth and confidence in the sector. In tandem, mobile device industry stakeholders have become more cautious triggering market uncertainties. Mobile Device Market Development Operating under such a backdrop, the development of mobile device ecosystems and vendor landscapes have been impacted severely. Many of these market pressures persisted throughout 2022 and now into 2023, borne chiefly by the smartphone market. According to the latest worldwide market study by ABI Research, worldwide smartphone shipments in 2022 declined 9.6 percent Year-over-Year